Biosimilars are biologic medical products highly similar to already approved reference products, with no clinically meaningful differences in terms of safety, purity, and potency. They have ...

Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, ...

Thus, it turns out that both sides in an earlier debate about biosimilars' impact on the biologic drug market ... their patients from original branded products to biosimilar equivalents.

AAM submitted comments to CMS, highlighting the extent and ways in which Part D sponsors and their PBMs engage in practices that favor, intentionally or unintentionally, more expensive reference drugs ...

Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative ...

The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. Beginning in 2023, five years after their European counterparts, patients ...

As this example shows, a long path lies between any approved biological drug and creating a biosimilar that can be used in patients.

The global biosimilars market size was valued at USD 28.70 billion in 2024 and is projected to reach from USD 33.16 billion in 2025 to USD 121.88 billion by 2033, growing at a CAGR of 15.56% during ...

EMA advisors at the Committee for Medicinal Products for ... said: “Biosimilars offer the NHS the potential to lower the cost per patient of using biologic treatments, facilitating responsible ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...